Azenta reported third-quarter fiscal 2026 results for the period ended June 30, 2026, with revenue from continuing operations of $161.2 million and non-GAAP diluted EPS of $0.16. Adjusted EBITDA from continuing operations was $18.5 million and adjusted EBITDA margin was 11.4%. The company noted organic revenue growth of 9% year over year and reiterated guidance for fiscal 2026 adjusted EBITDA of $59–62 million.

Financial Highlights

  • Revenue from continuing operations: $161.2 million for the quarter ended June 30, 2026 (up 12% year over year).
  • Gross profit (GAAP): $72.4 million; gross margin (GAAP): 44.9% for the quarter ended June 30, 2026.
  • Operating loss (GAAP) from continuing operations: $(4.2) million for the quarter.
  • Adjusted EBITDA — continuing operations: $18.5 million; Adjusted EBITDA margin: 11.4% for the quarter.
  • Non-GAAP diluted EPS — continuing operations: $0.16 for the quarter; GAAP diluted EPS from continuing operations: $(0.03); total diluted EPS: $0.05 (includes discontinued operations).

Business Highlights

  • Organic revenue growth of 9% year over year (excludes ~1ppt FX headwind and ~3ppt contribution from the UK Biocentre acquisition).
  • Sample Management Solutions revenue: $88 million, up 14% year over year, driven by Sample Repository Solutions and Consumables & Instruments (partially offset by lower Automated Stores revenue).
  • Multiomics revenue: $73 million, up 10% year over year, with strength in Next Generation Sequencing and Gene Synthesis partially offset by lower Sanger Sequencing revenue.
  • Company completed the sale of B Medical Systems (reported as discontinued operations); transaction closed July 1, 2026 (deposit of $28.0 million recorded at quarter end).
  • Operational actions include ongoing cost initiatives and transformation efforts; the quarter included costs related to quality remediation and rework activities in Automated Stores and higher R&D and SG&A investment.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.